Erlotinib in the treatment of advanced pancreatic cancer
Open Access
- 1 March 2008
- journal article
- Published by Taylor & Francis Ltd in Biologics: Targets and Therapy
- Vol. 2 (1), 83-95
- https://doi.org/10.2147/btt.s1832
Abstract
Peer reviewed article authored by (Robin K Kelley, Andrew H Ko). Read article or submit your manuscript for publishing.Keywords
This publication has 62 references indexed in Scilit:
- Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel MeetingCritical Reviews in Oncology/Hematology, 2008
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJama-Journal Of The American Medical Association, 2007
- Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trialCancer Chemotherapy and Pharmacology, 2006
- Clinical implications of the mechanism of epidermal growth factor receptor inhibitorsCancer, 2006
- Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor TherapyJournal of Clinical Oncology, 2006
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckJournal of Clinical Oncology, 2004
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002
- Radiation-induced Release of Transforming Growth Factor α Activates the Epidermal Growth Factor Receptor and Mitogen-activated Protein Kinase Pathway in Carcinoma Cells, Leading to Increased Proliferation and Protection from Radiation-induced Cell DeathMolecular Biology of the Cell, 1999